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Abstract Filamentous fungi represent an incredibly rich and
rather overlooked reservoir of natural products, which often
show potent bioactivity and find applications in different
fields. Increasing the naturally low yields of bioactive metab-
olites within their host producers can be problematic, and
yield improvement is further hampered by such fungi often
being genetic intractable or having demanding culturing con-
ditions. Additionally, total synthesis does not always represent
a cost-effective approach for producing bioactive fungal-
inspired metabolites, especially when pursuing assembly of
compounds with complex chemistry. This review aims at pro-
viding insights into heterologous production of secondary me-
tabolites from filamentous fungi, which has been established
as a potent system for the biosynthesis of bioactive com-
pounds. Numerous advantages are associated with this tech-
nique, such as the availability of tools that allow enhanced
production yields and directing biosynthesis towards ana-
logues of the naturally occurring metabolite. Furthermore, a
choice of hosts is available for heterologous expression, going
from model unicellular organisms to well-characterised fila-
mentous fungi, which has also been shown to allow the study
of biosynthesis of complex secondary metabolites. Looking to
the future, fungi are likely to continue to play a substantial role
as sources of new pharmaceuticals and agrochemicals—either
as producers of novel natural products or indeed as platforms
to generate new compounds through synthetic biology.
Keywords Fungi . Heterologous expression . Natural
products . Gene clusters . Secondary metabolites
Introduction
Bioactive natural products from filamentous fungi
Fungi and other microorganisms represent an invaluable source
of natural product (NP) bioactive compounds (Fig. 1), which
are exploited in various contexts, ranging from crop protection
to human medicine. In the last decades, drug discovery has
been greatly prompted by the increasing number of whole-
genome sequences that have become available, which exposed
amyriad of putative gene clusters for potentially bioactive com-
pounds. The approach quickly expanded from studies on bac-
teria to fungi as sequencing costs dropped and the technology
improved. Among fungal natural products, particular interest is
given to antimicrobials, due to the reduction in effectiveness of
existing antibiotics used to treat bacterial infections, which is
seen as a major threat to global health security (Aiken et al.
2014). Many prominent examples of compounds that affect our
everyday life fall into the group of fungal secondary metabo-
lites (SMs) (Hoffmeister and Keller 2007). Penicillins (1) and
cephalosporins (2), for instance, are β-lactam antibiotics and
represent the most widely used antimicrobials in the world:
cephalosporins accounting for 28% ($11.9 billion in 2009)
and penicillins for 19% ($7.9 billion in 2009) of the global
market of antibiotics (Hamad 2010). In addition to antibacterial
compounds, there are a number of fungal-derived antifungals
such as griseofulvin (3) and echinocandin (4) which have been
exploited for use in medicine. Another medical application that
fungal SMs are known for is that of cholesterol-lowering
agents, such as the statins, some of which act through selective
inhibition of squalene synthase and some others by hindering
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the activity of HMG-CoA reductase, the first enzyme involved
in biosynthesis of cholesterol (Istvan and Deisenhofer 2001).
This class of compounds includes lovastatin (5), which is pri-
marily produced by Aspergillus terreus, and mevastatin (6),
found in Penicillium citrinum (Manzoni and Rollini 2002).
Some other SMs produced from fungi can have immunosup-
pressant activity. An example is given by the non-ribosomal
peptide (NRP) cyclosporin (7), produced by Tolypocladium
niveum and widely used to avoid organ rejection in transplant
surgery (Weber et al. 1994). Other fungal-derived compounds
even display activities against multiple sclerosis, such as
fingolimod, a chemical derivative of the NP myriocin (8)
(Cohen et al. 2010).
Mycotoxins are also produced by fungi, as an example of
NPs whose presence as contaminants in food processing is
highly feared and monitored. Among the best known myco-
toxins, we find the aflatoxins (9), produced by Aspergillus
flavus (Hesseltine et al. 1966), the ochratoxins (10) from
Aspergillus and Penicillium spp. (Kuiper-Goodman and
Scott 1989), and the trichothecenes (11), found in Fusarium
sp. and other species (Sudakin 2003).
In some cases, fungal SMs may not be used directly as they
are found in nature, but be subjected to derivatisation to give
semisynthetic derivatives such as the enormous diversity of
the various penicillins, all of which start from the fungal fer-
mentation product. Alternatively, such secondary metabolites
penicillins (1)
cephalosporins (2)
griseofulvin (3) echinocandin (4)
mevastatin (6)
cyclosporin (7)
myriocin (8)
strobilurin A (12) tropolone (13) geodin (15)
tenellin (17)
desmethylbassianin (18)
ferrirhodin (19)
pleuromutilin (23)
ochratoxin A (10)
cladosporin (14)
lovastatin (5)
pravastatin (16)
aflatoxin b1 (9)
trichothecenes (11)
aphidicolin (20) paxilline (21)
aflatrem (22)
Fig. 1 Chemical structures of all fungal bioactive natural products mentioned in this article
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may serve as a model for the development of completely syn-
thetic derivatives. This is the case of the polyketide-based
strobilurin A (12) isolated from the basidiomycete
Strobilurus tenacellus (Anke et al. 1977), which inspired the
discovery and exploitation of β-methoxy-acrylic acid,
forming the basis of the strobilurin fungicides. This class of
antifungals includes one of the world’s most sold fungicides,
azoxystrobin (Bartlett et al. 2002).
Natural product gene clusters
SMs are usually produced by fungi through the catalytic
activity of one or more enzymes or sometimes through the
activity of large multifunctional polypeptides. When sev-
eral enzymes cooperate together towards the biosynthesis
of a SM, the corresponding genes tend to be forming a
gene cluster (Keller and Hohn 1997; Yu and Keller 2005;
Osbourn 2010). Such a situation was well known in bac-
teria and has become regarded as the normal situation in
fungi, and there is increasing evidence that the same prin-
ciple of gene clusters sometimes applies to plant second-
ary metabolic pathways (Nützmann and Osbourn 2014).
Clustering or co-localisation of the genes for a particular
product may occur for a number of reasons. Those cur-
rently most favoured are that it helps facilitate coordinated
regulation of all the genes by having them all in a similar
physical location. Another hypothesis is that it helps fa-
cilitate transmission of the entire pathway, either through
sexual transmission or indeed through horizontal transfer.
Clustering of genes that cooperate towards biosynthesis of
a NP greatly aids researchers in characterising and even
directing biosynthesis of the corresponding metabolite. Gene
clusters can be searched for within assembled genomes using
a range of bioinformatics tools, as has been widely reviewed
elsewhere (Weld et al. 2006; Brakhage and Schroeckh 2011;
Wiemann and Keller 2013; Yaegashi et al. 2014). Once a gene
cluster is identified, its full characterisation, as well as produc-
tion in high yields of the corresponding specialised metabo-
lite, can be achieved through heterologous expression
(Lazarus et al. 2014). This consists of cloning one or more
genes from a donor species and introducing them in a heter-
ologous (secondary) host. Heterologous expression is consid-
ered to be the best available option when pursuing character-
isation of biosynthetic genes in fungi that show slow growth in
laboratory conditions and have scarce availability of genetic
tools (Schmidt-Dannert 2015). Furthermore, it is often used as
a tool to increase production yields of bioactive NPs, frequent-
ly representing a more profitable alternative to total synthesis.
A certain degree of flexibility is encountered when choosing
which secondary host to use for heterologous expression of
the gene cluster of interest, ranging from unicellular model
organisms to well-characterised filamentous fungi.
Heterologous expression inEscherichia coli and yeast
hosts
One of the first successes for heterologous expression of fungal
secondary metabolite genes was that of 6-methylsalicylic acid
synthase (6-MSAS) from Penicillium patulum in Streptomyces
coelicolor (Bedford et al. 1995). Most research however has
focused on E. coli, given it is the best model prokaryotic host
for protein expression and purification. It has also been used to
recreate biosynthetic pathways for metabolites of interest or to
simply express a few genes from a cluster for partial recreation
of a pathway. Usually, the compounds that have been heterolo-
gously produced in E. coli are of bacterial origin. In this context,
a hallmark in heterologous production of complex non-
ribosomal peptide-polyketide hybrid (NRP-PK) natural prod-
ucts was established by Pfeifer et al. (2003), who recreated
complete biosynthesis of yersiniabactin (Ybt) in E. coli, upon
heterologous expression of its gene cluster in a previously
engineered strain of the model organism, which was able to
support correct post-translational processing of the synthase en-
zyme (Pfeifer et al. 2001). The results with expression of fungal
secondary metabolite genes in E. coli have been somewhat
mixed; whilst some groups have reported success, such as ex-
pression of 6-MSAS (Kealey et al. 1998), other research groups
have had only limited (if any) success with this system, partic-
ularly where expression of very large proteins such as non-
ribosomal peptide synthetases (NRPSs) or polyketide synthases
(PKSs) are concerned.
E. coli has many restrictions that prevent its use to recreate
entire fungal SM pathways. Firstly, this host has mainly been
used as a model organism and as a producer of heterologous
proteins, but it has not been developed as a SM secretion system.
E. coli cannot usually support post-translational modifications
that occur after protein synthesis and are required for functional-
ity of some enzymes. This is particularly important when the
core synthases such as PKSs and NRPSs need activation by
phosphopantetheinyl transferase or when cytochrome P450
oxidoreductases need suitable redox partners. An added compli-
cation is that E. coli has a different codon usage than higher
fungi, therefore sometimes requiring codon optimisation before
expression of the heterologous genes. Moreover, production of
antibiotics in E. coli may be challenging as the host could be
susceptible to the desired NP.
There have however been several examples of terpene cy-
clases being expressed in E. coli where just one fungal enzyme
needed to be expressed and without any post-translational modi-
fication (Schmidt-Dannert 2015). A more common way of using
E. coli to synthesise heterologous NPs is through purification of
the enzymes upon expression of foreign genes, followed by
incubation of the purified protein with its substrate in an in vitro
reaction. This can be useful when pursuing functional character-
isation of biosynthetic genes in a clean background. For example,
Davison et al. (2012) expressed the genes of the tropolone gene
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cluster from Penicillium stipitatum in E. coli and purified the
correspondent proteins. The product of the gene tropC, a
non-heme Fe(II)-dependent dioxygenase, was used to catalyse
in vitro conversion of 3-methylorcinaldehyde into tropolone
(13), therefore revealing the catalytic activity of this enzyme.
The yeast Saccharomyces cerevisiae is a unicellular model
ascomycete fungus with a long history of exploitation for
biotechnology, having been employed in many cases as a
recipient for production of heterologous molecules and recre-
ation of biosynthetic pathways for metabolites of interest. The
most prominent example so far is perhaps the production of
the sesquiterpene artemisinic acid, the precursor of the plant-
derived antimalarial drug artemisinin (Ro et al. 2006).
Several examples of heterologous biosynthesis of NPs
from higher fungi in yeast are also found in literature.
Ishiuchi et al. (2012) for instance developed a yeast-based
platform for heterologous expression of PKS and NRPS genes
from higher fungi. This encompasses an ad hoc-engineered
strain of S. cerevisiae and an expression vector that can be
assembled with the PKS or NRPS gene of interest using over-
lap extension PCR and yeast-based homologous recombina-
tion, which aid cloning of large synthase and synthetase genes
(typically from 5 to 20 kb). In this work, the products of five
PKSs and one NRPS from three different fungi were produced
heterologously and characterised. Furthermore, a previously
uncharacterised NRPwas identified, showing the applicability
of this system to genome mining (Ishiuchi et al. 2012). More
recently, Cochrane et al. (2016) have had success expressing
individual and multiple PKSs from the lichen fungus
Cladosporium cladosporioides to identify the enzymes re-
sponsible for synthesis of the antimalarial cladosporin (14).
As with E. coli, the yeast S. cerevisiae has also been
employed for purification of complex enzymes and
consequent characterisation of their catalytic activity through
in vitro reactions. For instance, Ma et al. (2009) purified the
highly reducing iterative polyketide synthase LovB (lovastatin
nonaketide synthase) from A. terreus, upon heterologous ex-
pression in S. cerevisiae, and characterised the catalytic activ-
ity of this megasynthase, as well as of its partner enoyl reduc-
tase enzyme LovB.
Enzymes of fungal origin are also produced using yeast as
heterologous host, as shown by Vaquero et al. (2015), who
produced a versatile sterol-esterase, active for both synthesis
and hydrolysis of triglycerides, from the fungus Ophiostoma
piceae. Ultimately, advantages of using the yeast S. cerevisiae
as a heterologous expression system are various: it is a unicel-
lular organism and has rapid growth, there are plenty of tools
available for genetic engineering, as a eukaryote, it can typically
support protein folding, and most, but not all, post-translational
modifications were required for functionality of eukaryotic pro-
teins. The yeast S. cerevisiae has also been given the status of
generally regarded as safe (GRAS) organism, as it is not pro-
ducing any known toxic or oncogenic product.
Heterologous expression in filamentous fungi
Besides E. coli and S. cerevisiae, filamentous fungi are often
chosen when complete biosynthesis of a fungal SM is pur-
sued. They usually have very simple growth requirements
and are often amenable to large-scale fermentation; indeed,
there is considerable experience in optimising the cultivation
of fungi such asPenicillium chrysogenum. Among the various
fungi, Aspergillus species are the most commonly used sec-
ondary hosts. Aspergillus nidulans is a genetic model species
among filamentous fungi and has been used also as
heterologous host to study gene clusters from other species.
Nielsen et al. (2013) developed a smart system for selectable
marker recycling in this host based on homologous integration
in the IS1 locus, which supports high levels of expression.
This approach allowed them for a stepwise transfer of all the
13 genes of the geodin (15) cluster from A. terreus into
A. nidulans, enabling to dissect the biosynthesis of the NP in
the secondary host. A more complex synthetic biology ap-
proach for production of the cholesterol-lowering agent prav-
astatin (16) was reported byMcLean et al. (2015). The authors
used P. chrysogenum to express the original compactin gene
cluster from P. citrinum, along with the gene CYP105AS1—
encoding a cytochrome P450—from Amycolatopsis orientalis
(also known as Streptomyces orientalis), converting the
compactin to pravastatin. The P. chrysogenum host they used
was a strain that had been derived from a commercial
penicillin-producing strain and had subsequently been manip-
ulated to lose its penicillin gene cluster. This host had there-
fore been through multiple rounds of conventional strain im-
provement, optimising its secondary metabolism potential un-
der fermentation conditions. This is also an example of how
heterologous platforms can be used to direct the biosynthesis
towards a derivative of the NP, bypassing or reducing the need
for expensive synthetic derivatisation. Besides recreating total
biosynthesis of SMs, heterologous expression has also the
potential of reprogramming the activity of PKSs and other
synthase enzymes, as shown by Fisch et al. (2011). In this
work, rational domain swaps were performed between the
PKSs for tenellin (17) and desmethylbassianin (18), followed
by heterologous expression of the hybrid synthases in
Aspergillus oryzae, and consequent isolation of compounds
where differences in chain length and methylation pattern
could be linked to the corresponding domain swaps.
A. oryzae is a species that has been used in many cases for
heterologous expression. This species is of particular interest as
it has a long history in food technology, since it has been used
for several centuries for the fermentation of cereals and legumes
to get commonly used food products like sake, miso, and soy
sauce, and it has been given the status of GRAS organism,
therefore safe to be used for the production of enzymes and
metabolites intended for human use (Barbesgaard et al. 1992).
A. oryzae also benefits from being taxonomically close to the
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genetic model A. nidulans, and many of the transformation
markers and regulatory elements in expression vectors can be
used in both species. Molecular tools have been established to
manipulate A. oryzae, such as selectable markers and promoters
that can ensure high levels of constitutive or inducible expres-
sion of foreign genes (Yamada et al. 1997; Jin et al. 2004a, b;
Pahirulzaman et al. 2012), which in turn can allow for high
yields of heterologous production of bioactive NPs (Table 1).
For instance, the biosynthesis of the polyketide tenellin (17)
from the entomopathogenic ascomycete Beauveria bassiana
was reproduced in A. oryzae (Heneghan et al. 2010). Four
genes, including a gene for an iterative PKS fused to a single
module NRPS, were inserted into A. oryzae by employing three
vectors. Each gene was flanked by the promoter PamyB and the
terminator TamyB from the Taka-amylase A gene from
A. oryzae, whose enzymatic product degrades starch into dextrin
(Tada et al. 1989); expression of this gene is induced by starch;
hence, its promoter is often used to drive inducible expression in
A. oryzae. The authors reported a titre of tenellin of 243 mg L−1
in A. oryzae (Heneghan et al. 2010), which was more than
fivefold higher than the production reported for the native host.
The use of promoters with high level of expression derived from
the secondary host is likely to have played an important role in
the high yield of heterologous product obtained. Munawar et al.
(2013) used A. oryzae to heterologously express the NRPS re-
sponsible for synthesis of the siderophore ferrirhodin (19) from
Fusarium sacchari. In other works, Fujii et al. (2011) expressed
four genes from a gene cluster of the plant pathogenic fungus
Phoma betae inA. oryzae, achieving production of the antibiotic
diterpene aphidicolin (20). A step-by-step transformation of
A. oryzae with the four genes of the aphidicolin cluster allowed
the authors to isolate the intermediates produced along the path-
way and characterise the catalytic activity of the enzymes
involved. In this case, the complementary DNA (cDNA) of
the four putative biosynthetic genes was used, therefore
avoiding potential problems related with the maturation of
mRNA in A. oryzae. The approach is not always straight for-
ward;A. oryzaemay encounter problemswith intron splicing, as
seen during heterologous expression of the ACE1 gene from
Magnaporthe oryzae (Song et al. 2015), as well as for 3-
methylorcinaldehyde synthase of Acremonium strictum
(Bailey et al. 2007). In other works, Tagami et al. (2013) suc-
cessfully synthesised the indole-diterpene paxilline (21) in
A. oryzae, a bioactive natural product that showsMRSA growth
inhibition. Six genes had first been identified as being involved
in biosynthesis of paxilline in the native producer Penicillium
paxilli (Saikia et al. 2006, 2007) and were expressed heterolo-
gously by Tagami et al. (2013). Also in this case, the authors
adopted a stepwise transformation approach and were therefore
able to isolate and identify the intermediate compounds of the
paxilline biosynthetic pathway. Ultimately, a yield of 35 mg L−1
of the final product was reported in A. oryzae. Adopting a sim-
ilar approach, the same research group also recreated biosynthe-
sis of aflatrems (22), indole-diterpene compounds with similar
structure and properties to those of paxilline (Tagami et al.
2014). Insertion of the first four genes of the pathway from the
original host A. flavus into A. oryzae allowed them to achieve
production of paspaline, a common precursor to aflatrems,
paxilline, and other indole-diterpenes. Further introduction of
the remaining three genes of the gene cluster led to biosynthesis
of the two final products aflatrem and β-aflatrem.
Another example of heterologous production of a fungal
SM in A. oryzaewas recently reported by Bailey et al. (2016),
who recreated total biosynthesis of the antibiotic
pleuromutilin (23), a diterpene compound naturally produced
by Clitopilus passeckerianus and related species (Hartley
et al. 2009). Despite the first developing a protocol for trans-
formation of the producing fungus (Kilaru et al. 2009), heter-
ologous expression of the putative gene cluster in the second-
ary host A. oryzae was preferred over manipulation within the
native producer, which is a known dikaryotic species. The
expression of the cDNA of the putative biosynthetic genes
allowed accumulation of pleuromutilin, as well as another
known product of fermentation of C. passeckerianus, 14-O-
acetyl-mutilin (Bailey et al. 2016). The expression vectors
developed by Pahirulzaman et al. (2012) were employed in
this case, where strong constitutive promoters derived from
genes involved in the primary metabolism drive expression of
the genes of interest. A remarkable tenfold increase in antibi-
otic production compared to the native host producer (final
Table 1 Reported yields of heterologous production of bioactive fungal natural products within the secondary host Aspergillus oryzae
Natural product Native host Bioactivity Reported yielda References
Citrinin Monascus purpureus Antibacterial 1.48 mg L−1 Sakai et al. (2008)
Tenellin Beauveria bassiana Inhibitor of erythrocyte membrane ATPase activity; iron chelator 243 mg L−1 Heneghan et al. (2010)
Aphidicolin Phoma betae Inhibitor of DNA polymerase α 0.33 mg L−1 Fujii et al. (2011)
Paxilline Penicillium paxilli Inhibitor of the high-conductance calcium-activated potassium channel; antibacterial 35 mg L−1 Tagami et al. (2013)
Aflatrem Aspergillus flavus Tremorgenic 54 mg Kg−1b Tagami et al. (2014)
Pleuromutilin Clitopilus passeckerianus Antibacterial 84 mg L−1 Bailey et al. (2016)
a The yield in the heterologous host is expressed as mg of compound produced per litre of liquid medium
b The yield, in this case, is expressed as mg of compound per Kg of rice, as the heterologous host was grown in a solid medium made of polished rice
(100 g) and adenine (10 mg) (Tagami et al. 2014)
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yield in A. oryzae 84 mg L−1) could be reported. Following up
on this work, the biosynthetic pathway for the antibiotic was
also dissected in the same secondary host, allowing to de-
scribe the catalytic activity of the enzymes involved (Alberti
et al. 2016). Worth mentioning is that for the first time, heter-
ologous total biosynthesis of a SM from a basidiomycete fun-
gus was recreated in an ascomycete secondary host, opening
the way for characterisation of other basidiomycete NPs in
better-known and more amenable hosts. As with many other
complex fungal SMs, total chemical synthesis of
pleuromutilin has only been achieved with extremely low
yields (0.7% overall yield to the final product in a 34-step
synthesis), as reported by Fazakerley et al. (2013). Due to
the energy consumption and high costs of the catalysts used,
large-scale production of pleuromutilin and other complex
fungal NPs through total synthesis is not economically feasi-
ble. Indeed, total biosynthesis of these bioactive compounds
through heterologous expression represents a far more appeal-
ing and inexpensive alternative.
Conclusions
Filamentous fungi can produce a wide range of SMs, which
have been exploited as pharmaceuticals for decades
(Hoffmeister and Keller 2007). Heterologous expression has
been established as a potent approach both for characterising
cryptic gene clusters from filamentous fungi and for achieving
production of bioactive NPs in a clean background, facilitat-
ing their purification and downstream applications.
In this review, the most common platforms for heterologous
biosynthesis of fungal NPs were analysed. Unicellular hosts,
E. coli in particular, have only rarely been used to recreate whole
biosynthetic pathways from fungi, despite representing a suit-
able platform for purification and study of individual enzymes.
In contrast, plenty of tools have been developed for the genetic
manipulation of Aspergillus and other filamentous fungi used as
heterologous hosts, going from recycling of selectable markers
(Nielsen et al. 2013) to multigene expression vectors
(Pahirulzaman et al. 2012). When the genome of the species
of interest has been sequenced and assembled, synthetic gene
sequences, based on the most likely predicted coding sequence
for the genes under study, can nowadays be obtained rather
inexpensively. These can consequently be assembled in suitable
vectors for constitutive or inducible expression in the preferred
filamentous fungus heterologous host, making it unnecessary to
even culture the donor organism. Given the successful examples
of biosynthetic pathways recreated in the last years through
heterologous expression, it can be envisaged that this will enable
characterisation of many other SMs from fungi in the future not
only for the production of naturally occurring compounds but
also for refactoring of metabolic pathways and consequent pro-
duction of novel metabolites through synthetic biology.
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